GAVI ALLIANCE

THE VACCINE GOAL: INTRODUCE AND SCALE UP VACCINESWITH THE EXCEPTION OF PENTAVALENT VACCINE, IN AGGREGATE ALL GAVI-SUPPORTED VACCINES HAD HIGHER COVERAGE IN 2023 THAN BEFORE THE PANDEMIC IN 2019.- 34 GAVI-SUPPORTED VACCINE INTRODUCTIONS AND PREVENTIVE CAMPAIGNS TOOK PLACE IN 2023 IN ADDITION TO 40 OUTBREAK RESPONSE VACCINATION CAMPAIGNS SUPPORTED BY GAVI.- 14 MILLION GIRLS FULLY IMMUNIZED AGAINST HPV WITH GAVI SUPPORT IN 2023 MORE THAN THE PREVIOUS TEN YEARS COMBINED.- 15 COUNTRIES ACCESSED CHOLERA, MENINGOCOCCAL AND YELLOW FEVER VACCINES THROUGH GAVI-SUPPORTED EMERGENCY STOCKPILES A TOTAL OF 29 TIMES IN 2023.- 57 GAVI-SUPPORTED COUNTRIES INCREASED BREADTH OF PROTECTION WITH VACCINES IN THE GAVI PORTFOLIO TO 56%, UP 3 PERCENTAGE POINTS FROM 2022.THE EQUITY GOAL: STRENGTHEN HEALTH SYSTEMS TO INCREASE EQUITY IN IMMUNIZATIONIN GAVI 5.0/5.1, HEALTH SYSTEM STRENGTHENING (HSS) SUPPORT PRIORITIZES EQUITY IN IMMUNISATION DELIVERY, TO REDUCE THE NUMBER OF ZERO-DOSE AND UNDER-IMMUNIZED CHILDREN.- >69 MILLION CHILDREN WERE REACHED WITH GAVI-SUPPORTED ROUTINE VACCINES IN 2023 MORE THAN IN ANY YEAR APART FROM 2019.- 47 COUNTRIES HAVE INSTALLED MORE THAN 67,000 COLD CHAIN EQUIPMENT (CCE) UNITS PROCURED BY UNICEF SUPPLY DIVISION THROUGH GAVI'S COLD CHAIN EQUIPMENT OPTIMIZATION PLATFORM (CCEOP) NEARLY 5,200 IN 2023 ALONE.- AFTER SEVERAL YEARS OF DECLINE SINCE 2019, AVERAGE COVERAGE OF DTP3 IN 26 LOW-INCOME COUNTRIES SUPPORTED BY GAVI HELD STEADY IN 2023 THE ONLY INCOME GROUP TO AVOID DECLINE.- 32 COUNTRIES WERE APPROVED FOR EQUITY ACCELERATOR FUND (EAF) FUNDING TO IDENTIFY AND REACH ZERO-DOSE CHILDREN AND MISSED COMMUNITIES.- IN 2023, GAVI-SUPPORTED COUNTRIES MAINTAINED DTP3 COVERAGE AT 80% (COMPARED TO THE 84% GLOBAL AVERAGE).THE SUSTAINABILITY GOAL: IMPROVE SUSTAINABILITY OF NATIONAL IMMUNIZATION PROGRAMSTHE YEAR 2023 CONFIRMED THE ROBUSTNESS OF THE VACCINE ALLIANCE'S CO-FINANCING APPROACH AND THE STEADY FINANCIAL COMMITMENT OF COUNTRIES, DESPITE MANY COUNTRIES FACING INCREASING FRAGILITY.- US$ 215 MILLION WAS CONTRIBUTED BY COUNTRIES TOWARDS THE CO-FINANCING OF GAVI-SUPPORTED VACCINES IN 2023 THE HIGHEST AMOUNT YET AND A TESTAMENT TO COUNTRY OWNERSHIP AND THE LONG-TERM FINANCIAL SUSTAINABILITY OF GAVI-SUPPORTED VACCINES.- 55 VACCINE PROGRAMS ORIGINALLY INTRODUCED WITH GAVI FUNDING ARE NOW SELF-FINANCED BY COUNTRIES AS OF 2023, UP FROM 40 IN 2018.- 100% OF COUNTRIES FULLY MET THEIR 2023 CO-FINANCING OBLIGATION EXCEPT FOUR WAIVERS FOR HUMANITARIAN CRISIS.- IN THE FACE OF FISCAL CHALLENGES, CLIMATE CHANGE, CONFLICT AND INSTABILITY, MOST GAVI-SUPPORTED COUNTRIES MAINTAINED OR INCREASED DOMESTIC RESOURCES FOR CO-FINANCING OF GAVI-SUPPORTED VACCINES IN 2023, BRINGING TO US$ 1.7 BILLION THEIR TOTAL CONTRIBUTION SINCE THE INTRODUCTION OF THE CO-FINANCING POLICY IN 2008.THE HEALTHY MARKETS GOAL: ENSURE HEALTHY MARKETS FOR VACCINES AND RELATED PRODUCTSGAVI'S MARKET SHAPING EFFORTS MAKE LIFE-SAVING VACCINES AND OTHER IMMUNISATION PRODUCTS MORE ACCESSIBLE AND AFFORDABLE FOR LOWER-INCOME COUNTRIES.- 10 MARKETS FOR VACCINES AND IMMUNISATION PRODUCTS EXHIBITED ACCEPTABLE LEVELS OF HEALTHY MARKET DYNAMICS IN 2023, MEETING THE TARGET FOR THE YEAR.- 10 INNOVATIVE PRODUCTS WERE WITHIN THE PIPELINE OF COMMERCIAL-SCALE MANUFACTURERS IN 2023, CONTINUING TO EXCEED THE ALLIANCE TARGET OF 8 BY 2025 WELL AHEAD OF SCHEDULE..- 1 NEW PRODUCT WITH IMPROVED CHARACTERISTICS WAS NEWLY OFFERED TO GAVI-SUPPORTED COUNTRIES IN 2023, KEEPING THE ALLIANCE ON TRACK FOR ITS 2025 TARGET: MULTIVALENT MENINGOCOCCAL CONJUGATE VACCINE (MMCV), THE FIRST CONJUGATE VACCINE TO PROTECT AGAINST THE FIVE PREDOMINANT SEROGROUPS OF MENINGOCOCCAL MENINGITIS IN AFRICA.- THROUGH GAVI'S MARKET SHAPING EFFORTS, THE NUMBER OF MANUFACTURERS SUPPLYING PREQUALIFIED GAVI-SUPPORTED VACCINES REMAINED AT 19 IN 2023 (WITH MORE THAN HALF BASED IN LOW- AND MIDDLE-INCOME COUNTRIES) COMPARED WITH 5 IN 2001.FURTHER INFORMATION ON GAVI'S PROGRESS TOWARDS ACHIEVING ITS STRATEGIC GOALS CAN BE FOUND IN ITS 2023 ANNUAL PROGRESS REPORT, ONLINE AT: HTTPS://WWW.GAVI.ORG/PROGRAMMES-IMPACT/OUR-IMPACT/PROGRESS-REPORTS.